I read with interest the study by Stephens et al. 1 assessing the influence of fluid regimens in the first week of life on patent ductus arteriosus (PDA) in infants p1250 g birth weight and p32 weeks gestational age. The authors conclude, after controlling for gestational age and illness severity, that high fluid intake on days 2 and 3 of life is a significant predictor of PDA, with fluid intake above 170 ml kg À1 day À1 on day 3 of life associated with increased risk of PDA among infants p1250 g. I have a few questions and comments to add regarding this study.
In the Methods, the authors note that all infants in this cohort received prophylactic indomethacin and 10% of infants developed PDA. 1 In comparison to other studies, this PDA incidence seems quite low. The incidence of a symptomatic PDA among extremely low birth weight (ELBW) infants is reported to be 55 to 70%.
2 A large multicenter randomized control trial (TIPP trial) of infants <1000 g birth weight showed that indomethacin prophylaxis reduced the incidence of symptomatic PDA from 50% (placebo) to 24%. 3 The low PDA incidence in the study by Stephens et al. 1 may have been secondary to indomethacin prophylaxis and/or because they only included infants that survived to discharge, which might limit the ability to generalize their findings to initial fluid management. Also, indomethacin treatment may have modified the infants' tolerance to different fluid management strategies by decreasing the impact of an open ductus arteriosus in relation to morbidity outcomes. In their study, it cannot be deciphered whether PDA affected fluid management or fluid management affected PDA. Therefore, their results may not be applicable to infants that did not get prophylactic indomethacin.
Hemodynamically significant symptomatic PDA is associated with serious comorbidities such as congestive heart failure, pulmonary hemorrhage and bronchopulmonary dysplasia. 2 The authors mention that fluid intake did not predict the development of bronchopulmonary dysplasia when controlling for other known risk factors. Did any infants in the study develop pulmonary hemorrhage? Prophylactic indomethacin treatment may have prevented many of the known complications associated with PDA and skewed the results attributed to fluid volume amounts. As all infants in the study received indomethacin, were there any cases of gastrointestinal perforation? And if so, were those cases associated with a specific fluid regimen? Also, were there any infants that developed oliguria and/or high serum creatinine levels, possibly related to indomethacin treatment, which could have affected the weight-loss/gain results?
As the authors mention, infants with lower birth weight and gestational age are at higher risk of bronchopulmonary dysplasia and PDA. Maturational effects may explain the noted differences in PDA incidence between the study groups, with fluid regimen being more of an association versus a directly causative effect in relation to PDA. The effect of maturation is reflected in a study by Koch et al. 4 that demonstrated persistent PDA in 56% of ELBW infants with a nearly threefold increase in the spontaneous PDA closure rate between ELBW infants <25 and 25 to 26 weeks of estimated gestational age (EGA) and an additional twofold increase after 29 weeks of EGA (P ¼ 0.002). The 122 infants in the Koch et al. 4 study received fluid therapy in the initial 48 h averaged B100 ml kg À1 day
À1
. In preterm infants, the ductus arteriosus, whether spontaneously or indomethacin mediated, frequently fails to achieve significant ischemia levels required to cause anatomic vessel remodeling, allowing persistent ductal patency or if functionally closed, a tendency to reopen. 2 As the study by Stephens et al. 1 suggests, fluid regimens at critical periods of development certainly could play a role in PDA closure. However, without having randomized infants to different fluid regimens, it is difficult to comment on the true impact of fluid management on the PDA. It is conceivable that the more physiologically immature infants received increased fluid volumes in response to clinical signs of dehydration and these infants were already predisposed to have a worse outcome due to their immature physiology. Therefore, increased fluid volume in the first week could be simply a marker of a higher risk infant, as the score for neonatal acute physiology, perinatal extension, version II (SNAPPE-II) scores reflected in this study subgroup.
The influence of fluid regimens on the PDA remains of great interest. In a retrospective analysis, fluid intake alone is insufficient information to make a conclusion about hydration status or management intentions. From this study, it would be premature to conclude that fluid management impacts the risk of PDA. The authors, after controlling for gestational age and illness severity, have demonstrated an association of PDA in infants p1250 g with high fluid intake on days 2 and 3 of life, which cannot be interpreted as evidence of cause-and-effect. To guide ideal practice strategies in ELBW infants, future randomized, blinded studies are needed to Fluid regimens and the risk of patent ductus arteriosus in extremely low birth weight infants We appreciate Dr McAdams' thoughtful comments regarding our manuscript. 1 As noted, the 10% rate of symptomatic patent ductus arteriosus (PDA) in our population is lower than the rate of 55 to 70% reported by Hermes-DeSantis and Clyman 2 or the rate in infants who receive prophylactic indomethacin versus controls reported by Schmidt et al. 3 (24 versus 50%). This may in part be explained by the differences in our study population. While Hermes-DeSantis and Clyman 2 and Schmidt et al. 3 each report on the rates of symptomatic PDA in infants born <1000 g or <28 weeks gestation, our population included more mature infants up to 1250 g and 32 weeks gestation. These higher gestation infants have lower rates of all neonatal morbidities including PDA. Two previous studies of infants born <1500 g report lower rates of symptomatic PDA (16 to 19%). 4, 5 Our population is unique, in that all infants received prophylactic indomethacin, and therefore, these results may not be generalizable to infants who do not receive indomethacin prophylaxis.
As Dr McAdams points out, our study concludes that high fluid intake is associated with the increased rate of symptomatic PDA among infants <1250 g. We do not report direct cause and effect of fluid regimen on the rate of PDA and we do not conclude that the fluid management on days 2 and 3 of life causes PDA. However, the average time of presentation of symptomatic PDA has been reported to range from 10±6 to 14.7±3 days of life. 4, 5 Thus, fluid management on days 2 and 3 of life cannot be influenced by the presence of PDA, which does not generally appear until days later. It is also true that maturation and illness severity effect rates of morbidities, with lower birth weight, lower gestational age infants having lower rates of morbidity including PDA. 6 However, we controlled for gestational age and SNAPPE-2 (which includes birth weight) in our regression models. Thus, the association we report between fluid and PDA has accounted for maturational effects and acute illness severity.
A retrospective study is always plagued by limitations. We did not analyze associations between fluid regimen and pulmonary hemorrhage, intestinal perforation, oliguria or elevated serum creatinine levels as the incidence of these complications is low in our neonatal intensive care unit. The effects of weight loss or gain as a marker of fluid status independent of fluid intake were examined.
We agree with Dr McAdams' that the true impact of fluid management on PDA and the physiologic mechanisms that play a role can only be assessed in a randomized control trial.
